AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
Study NCT05556629 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT00780650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 80 mg oral dose, once per day for 6 weeks
Study NCT00780650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80 mg dose once per day for 6 weeks
Study NCT04543617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Study NCT04543617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT04543617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab Matching Placebo
Description: Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT04543617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT04543617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab Matching Placebo
Description: Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study NCT02875314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction
Description: vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
Study NCT02875314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Cycle Intensive Chemotherapy
Description: Carboplatin, thiotepa, etoposide
Study NCT02875314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandem 3 Cycle Intensive Chemotherapy
Description: Carboplatin, thiotepa
Study NCT03224949 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Patients will have a one time blood draw
Study NCT01728792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV IM or SC injection
Study NCT01224925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping with Dycal
Description: Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
Study NCT01224925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping
Description: WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
Study NCT04581421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carb Low Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
Study NCT04581421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb High Fat Diet
Description: The participants will be randomized to a diet of low carb/ high fat og high carb/low fat
Study NCT01203930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablets administered orally twice daily
Study NCT01203930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
Study NCT03237858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartLogic ON
Description: Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
Study NCT03237858 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HeartLogic OFF
Description: Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
Study NCT02422719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: Radotinib 400mg bid
Study NCT00245102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT04083716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Reference Formulation
Description: ABI-H2158 tablets Reference Formulation
Study NCT04083716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158 Test Formulation
Description: ABI-H2158 tablets Test Formulation
Study NCT05604716 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: observational study
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
Study NCT02463929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
Study NCT02126683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study NCT04016779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily
Study NCT04016779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Description: SPN-812 will be administered once daily and compared to Placebo
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical for: Solution for infusion Route of administration: Intravenous
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules Route of administration: Oral
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsules Route of administration: Oral
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or equivalent
Description: Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine or equivalent
Description: AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
Study NCT04270409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
Study NCT01529008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core decompression/PREOB® implantation
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
Study NCT02996123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cad/cam maxillary dentures
Description: patients wearing cad/cam designed and milled dentures
Study NCT01529008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Core decompression/placebo implantation
Description: All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
Study NCT00231673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
Study NCT02996123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cad/cam maxillary dentures
Description: patients wearing cad/cam designed and milled dentures
Study NCT02878265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A supplements
Study NCT02878265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A and ZInc
Description: Combination of vitamin A and zinc supplements
Study NCT02878265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A , Zinc and Multivitamin
Description: Combination of vitamin A, zinc and multivitamins
Study NCT03337178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blinded Fitbit
Description: Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
Study NCT03337178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit is worn for 3 months post-operatively with feedback and step goals
Study NCT02833415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [U-13C3] glycerol
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
Study NCT02833415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [U-13C3] glycerol
Description: Ingestion of \[U-13C3\] glycerol based on human's body weight such as (50 mg/kg body weight).
Study NCT02833415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Active drug
Study NCT02833415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Empagliflozin)
Description: Placebo tablet manufactured to mimic EMPA 10 mg tablet.
Study NCT02098993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Study NCT01255371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir
Description: Evaluation of second line antiretroviral regimen including boosted lopinavir
Study NCT01255371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Evaluation of second line antiretroviral regimen including boosted atazanavir
Study NCT04516148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Dosing per hospital policy
Study NCT04516148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Dosing per hospital policy
Study NCT00491309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
Study NCT02487784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block allograft
Description: A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
Study NCT02487784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Particulate allograft + autogenous bone chips
Description: The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
Study NCT02215577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-situ split
Description: The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
Study NCT01575652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group using angiotensin converting enzyme inhibitor
Description: Measurement of peritoneal protein loss level with use of ACEIs
Study NCT01575652 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Group not using angiotensin converting enzyme inhibitor
Description: Measurement of peritoneal protein loss level without usage of ACEIs
Study NCT01364688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral alfacalcidol
Description: Oral alfacalcidol 0.5 microgram per day
Study NCT01364688 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: no drug
Description: no drug
Study NCT03647579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine
Description: midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
Study NCT03647579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine
Description: Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
Study NCT00594100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE Flow Reversal System (GFRS)
Description: Carotid artery angioplasty and stenting with embolic protection
Study NCT03451994 — intervention group
Intervention type: OTHER
Intervention: Breath test
Description: Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
Study NCT03451526 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
Study NCT03331848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: BID
Study NCT03331848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331 - 20mg
Description: Oral
Study NCT02215577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal embolization or ligation
Description: Portal vein embolization is performed according to the intervention used at the different sites.
Study NCT04529148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dropping pills，best western medicine treatment
Description: oral
Study NCT04529148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment
Description: oral
Study NCT03308448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
Study NCT01643902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
Study NCT03078751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth.
Study NCT02840383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: Schools not receiving intervention until two years after implementation.
Study NCT02840383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: intervention at the beginning of study.
Study NCT02958215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
Study NCT02958215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml normal saline will be given before spinal anesthesia
Study NCT02544464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose 1000 mg
Description: Ferric carboxymaltose is administered after anesthesia induction
Study NCT02544464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (normal saline) is administered after anesthesia induction
Study NCT01058538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
Study NCT04084223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study).
Study NCT02724228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: BMN 111 will be administered subcutaneously daily.
Study NCT01528449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B.microti diagnostic blood tests
Description: the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
Study NCT02385734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT02385734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap
Description: Periodontal plastic surgery technique
Study NCT02385734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Flap
Description: Periodontal plastic surgery technique
Study NCT02352441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Intentions(II)
Description: Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals.
Study NCT02421562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: training in hypnoanalgesia
Description: training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
Study NCT03386032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational OTC Cream
Description: Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
Study NCT03386032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Desonide
Description: Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.
Study NCT03386032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.